Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?

Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could DYN face a similar situation as it did in 2021 and 2023 and underperform the S&P over the next 12 months — or will it see a strong jump? The $39 average of analysts' price estimate reflects a little over 10$35. Note that Dyne doesn't have any marketable product yet, and its valuation is purely based on its pipeline potential. Moreover, smaller pharmaceutical firms ...